| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e29526f284c0155fd79806c9dd5a1c7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2020-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cf3fe94cc4ced23d2ad3c4ee0d16d0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f684324f41e9901af69e9791cce627a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44540c5ae2d73b7ed3a2dc79199f7e6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29e2a3a65203904bd7c7eb2517d7bb18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_613597b51a292687f7313a120b716abf |
| publicationDate |
2020-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020185672-A1 |
| titleOfInvention |
Anti-cd38 agents for desensitization and treatment of antibody-mediated rejection of organ transplants |
| abstract |
Methods and systems for desensitizing a human leukocyte antigen (HLA) sensitized subject to prepare for an organ transplant with an improved transplant survival and function, and/or treating or reducing the likelihood of antibody mediated rejection (ABMR) of an organ transplant in a subject are provided, generally including administering an effective amount of an anti-CD38 antibody or a CD38-targeting therapy to reduce the symptoms or ABMR or HLA levels. The subject in the methods may have developed or is experience drug-resistant sensitization, and to whom standard techniques like intravenous immunoglobulin and plasmapheresis are ineffective. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022184676-A1 |
| priorityDate |
2019-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |